These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 18519690)
21. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma. McBride MJ; Pulice JL; Beird HC; Ingram DR; D'Avino AR; Shern JF; Charville GW; Hornick JL; Nakayama RT; Garcia-Rivera EM; Araujo DM; Wang WL; Tsai JW; Yeagley M; Wagner AJ; Futreal PA; Khan J; Lazar AJ; Kadoch C Cancer Cell; 2018 Jun; 33(6):1128-1141.e7. PubMed ID: 29861296 [TBL] [Abstract][Full Text] [Related]
22. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Su L; Sampaio AV; Jones KB; Pacheco M; Goytain A; Lin S; Poulin N; Yi L; Rossi FM; Kast J; Capecchi MR; Underhill TM; Nielsen TO Cancer Cell; 2012 Mar; 21(3):333-47. PubMed ID: 22439931 [TBL] [Abstract][Full Text] [Related]
23. SYT-SSX fusion genes in synovial sarcoma of the thorax. Yano M; Toyooka S; Tsukuda K; Dote H; Morimoto Y; Ohata N; Ichimura K; Aoe M; Date H; Shimizu N Lung Cancer; 2004 Jun; 44(3):391-7. PubMed ID: 15140553 [TBL] [Abstract][Full Text] [Related]
24. When used together SS18-SSX fusion-specific and SSX C-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases. Zaborowski M; Vargas AC; Pulvers J; Clarkson A; de Guzman D; Sioson L; Maclean F; Chou A; Gill AJ Histopathology; 2020 Oct; 77(4):588-600. PubMed ID: 32559341 [TBL] [Abstract][Full Text] [Related]
28. Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. Nielsen TO; Poulin NM; Ladanyi M Cancer Discov; 2015 Feb; 5(2):124-34. PubMed ID: 25614489 [TBL] [Abstract][Full Text] [Related]
29. A novel type of SYT/SSX fusion: methodological and biological implications. Törnkvist M; Brodin B; Bartolazzi A; Larsson O Mod Pathol; 2002 Jun; 15(6):679-85. PubMed ID: 12065783 [TBL] [Abstract][Full Text] [Related]
30. Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes. El Beaino M; Rassy E; Hadid B; Araujo DM; Pavlidis N; Lin PP Curr Oncol Rep; 2020 Oct; 22(12):124. PubMed ID: 33025259 [TBL] [Abstract][Full Text] [Related]
31. Proteomic signatures corresponding to the SS18/SSX fusion gene in synovial sarcoma. Ishii M; Suehara Y; Sano K; Kohsaka S; Hayashi T; Kazuno S; Akaike K; Mukaihara K; Kim Y; Okubo T; Takamochi K; Takahashi F; Kaneko K; Saito T Oncotarget; 2018 Dec; 9(101):37509-37519. PubMed ID: 30680066 [TBL] [Abstract][Full Text] [Related]
32. Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo. Takenaka S; Naka N; Araki N; Hashimoto N; Ueda T; Yoshioka K; Yoshikawa H; Itoh K Int J Oncol; 2010 Apr; 36(4):823-31. PubMed ID: 20198325 [TBL] [Abstract][Full Text] [Related]
33. Mechanisms of HDAC inhibitor-induced thrombocytopenia. Matsuoka H; Unami A; Fujimura T; Noto T; Takata Y; Yoshizawa K; Mori H; Aramori I; Mutoh S Eur J Pharmacol; 2007 Oct; 571(2-3):88-96. PubMed ID: 17628529 [TBL] [Abstract][Full Text] [Related]
34. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329 [TBL] [Abstract][Full Text] [Related]
35. Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma. Raquib AR; Hofvander J; Ta M; Nielsen TO Appl Immunohistochem Mol Morphol; 2022 Sep; 30(8):531-539. PubMed ID: 35880992 [TBL] [Abstract][Full Text] [Related]
36. Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability. Benabdallah NS; Dalal V; Scott RW; Marcous F; Sotiriou A; Kommoss FKF; Pejkovska A; Gaspar L; Wagner L; Sánchez-Rivera FJ; Ta M; Thornton S; Nielsen TO; Underhill TM; Banito A Nat Struct Mol Biol; 2023 Nov; 30(11):1640-1652. PubMed ID: 37735617 [TBL] [Abstract][Full Text] [Related]
37. Combination of HDAC and FYN inhibitors in synovial sarcoma treatment. Parker K; Zhang Y; Anchondo G; Smith A; Guerrero Pacheco S; Kondo T; Su L Front Cell Dev Biol; 2024; 12():1422452. PubMed ID: 39045458 [TBL] [Abstract][Full Text] [Related]
38. Primary pulmonary synovial sarcoma confirmed by molecular detection of SYT-SSX1 fusion gene transcripts: a case report and review of the literature. Hosono T; Hironaka M; Kobayashi A; Yamasawa H; Bando M; Ohno S; Sohara Y; Sugiyama Y Jpn J Clin Oncol; 2005 May; 35(5):274-9. PubMed ID: 15879502 [TBL] [Abstract][Full Text] [Related]
39. Histone acetylation is not an accurate predictor of gene expression following treatment with histone deacetylase inhibitors. Ellis DJ; Lawman ZK; Bonham K Biochem Biophys Res Commun; 2008 Mar; 367(3):656-62. PubMed ID: 18179771 [TBL] [Abstract][Full Text] [Related]
40. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma. Carmody Soni EE; Schlottman S; Erkizan HV; Uren A; Toretsky JA Clin Orthop Relat Res; 2014 Mar; 472(3):874-82. PubMed ID: 23716114 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]